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Abstract
Background: The ocular manifestations of HIV may lead to visual impairment or blindness. In India,
patients typically initiate antiretroviral treatment (ART) with low CD4 cell counts when the risk of ocular
complications may be high. The objective of this study was to determine the prevalence and types of HIV-
associated ocular conditions in patients referred for ART in India.
Methods: This cross-sectional study was undertaken at a large public sector ART centre in Mumbai, India.
Data collection including a standardised symptom screen, and an ophthalmic examination were performed
on all consecutive patients satisfying the criteria for enrolment into the ART clinic irrespective of the
presence or absence of ophthalmic/visual symptoms.
Results: Enrolled patients (n = 149) had a median CD4 cell count of 180 cell/μL (inter-quartile range
[IQR], 106-253 cells/μL). The prevalence of HIV-associated ocular disease was 17.5% (95% CI, 11.2-23.6%)
in all participants and 23.8% (95% CI: 14.5-33.1) in those with CD4 cell counts <200 cells/μL (n = 84). Only
7.7% of patients with HIV-associated ocular disease reported any eye symptoms in the standardised
symptom screen. Objective visual impairment was detected in 20% of those with HIV-associated ocular
disease compared to 6% in those without ocular manifestations (p = 0.02). Vitreoretinal disease was the
most common manifestation, of which cytomegalovirus retinitis (CMVR) was the most frequent retinal
infection (overall prevalence 8.7%, 95% CI: 4.1-13.3%). In a multivariable analysis, HIV-associated ocular
disease was independently associated with a CD4 count <100 cells/μL (odds ratio [OR], 6.3, 95% CI: 1.5-
25.9) and WHO clinical stages 3 and 4 (OR 9.4, 95% CI: 2.4-37.2). However, symptoms were not
independently predictive of ocular disease. Sensitivity of ocular symptom screening was 7.7%, with a
positive predictive value of 18% in this population.
Conclusion: Over a fifth of unselected patients who are eligible for ART in this setting have HIV-related
ocular disease of which CMVR is the most common form. Such patients may be at risk of developing ocular
immune reconstitution phenomena during ART. Screening for ocular symptoms is not a reliable method
to identify those with ocular morbidity and this highlights the need for routine ophthalmic screening prior
to commencement of ART.
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Background
HIV-related eye disease may affect 50-75% of HIV-
infected people worldwide at some point during the
course of their illness [1]. This generally takes the form of
opportunistic infections that can affect any of the ocular
tissues, from the eyelids to the retina. In particular, those
conditions affecting the retina may lead to chronic visual
impairment or blindness. The spectrum of HIV-related
disease appears to differ by geographic location, with
reports suggesting that infection-related retinitis is not as
common in sub-Saharan Africa compared to industrial-
ised countries and South Asia [2-4]. The very low preva-
lence of CMVR seen in sub-Saharan Africa may not be a
direct reflection of lower incidence, but possibly reflect
that these patients die from systemic opportunistic infec-
tions before their CD4 counts fall low enough to allow the
development of HIV-related eye disease [2,3,5]. In sub-
Saharan Africa, anterior segment conditions such as her-
pes zoster ophthalmicus are more common than posterior
segment (retinal) opportunistic infections [3]. The situa-
tion is less clear in South Asia - ocular manifestations of
HIV in India were first reported in 1995 [4]. Since then,
the number of patients affected by HIV has greatly
increased, and the patient demographic is likely to have
changed.
The immune reconstitution inflammatory syndrome
(IRIS) is a well recognised complication of antiretroviral
therapy (ART), which may lead to the clinical deteriora-
tion of opportunistic infections due to the rapid restora-
tion of immunological host responses during the initial
weeks of treatment [6]. Immune recovery uveitis (IRU) is
the predominant form of ocular IRIS and mainly occurs in
patients with pre-existing CMVR at the time of ART initia-
tion [7]. IRU is characterised by ocular inflammation fol-
lowing ART initiation and can result in visual loss from
macular oedema, retinal neovascularisation and cataract
[7,8]. With increasing availability of antiretroviral ther-
apy, IRU may play a significant role in contributing to
ocular morbidity. Identification and treatment of ocular
disease prior to ART initiation is, therefore, important.
Current estimates suggest that between 2-3.1 million peo-
ple are diagnosed with HIV in India [9]. The Government
of India launched a free public sector ART initiative in
2004 and access to ART is steadily increasing [10]. The
estimated prevalence of HIV-related eye disease in India is
reported to be between 8-45% [4,11,12], but population
demographics were different in each study making com-
parisons difficult. Data are scarce concerning the burden
of ocular disease in patients initiating ART from low CD4
counts in resource-limited countries, who are likely to be
at high risk of ocular opportunistic infections. Previous
prevalence estimates have generally been within popula-
tions selected on the basis of symptoms or ophthalmolog-
ical referral. To our knowledge, there have been no studies
to date in the Indian sub-continent that have evaluated
the prevalence of HIV-related ocular lesions in an unse-
lected, ART-naïve population. The aim of this study was to
conduct an epidemiological study of HIV-related eye-dis-
ease (in particular vitreoretinal disease) in all HIV-
infected adults, prior to commencing ART attending a
large HIV referral and ART centre in Mumbai, India.
Methods
Study setting and patients
This cross-sectional study was carried out at the ART Cen-
tre, Sir JJ Hospital, Mumbai - a tertiary referral centre and
teaching hospital. The ART centre is recognised as a
National AIDS Control Organisation (NACO) ART Centre
of Excellence. It is the largest ART centre in India and pro-
vides free ART medication to all registered clinic attend-
ees. ART is initiated in patients with CD4 counts <250
cells/μL or with a prior AIDS diagnosis (WHO clinical
stage 4 disease), according to NACO guidelines [13]. All
patients attending the clinic over a 2-month period were
recruited irrespective of ophthalmic symptoms or history
or CD4 count. Demographic and medical information
was obtained by a combination of direct questioning by
the ART clinic counsellor, and review of the medical case
notes. Data obtained included mode of transmission,
present CD4 count, WHO clinical stage and duration
since HIV diagnosis. None of this information was dis-
closed to personnel conducting the ophthalmic examina-
tion. In addition, standardised symptom screening was
conducted as related to ocular pathology; this included
questions relating to impairment of vision, ocular pain
and presence of floaters.
Ophthalmic examinations
Ophthalmic examinations were conducted by an ophthal-
mologist. Presenting and best-corrected visual acuity was
measured using Log MAR (logarithm of the minimal
angle of resolution) visual acuity charts, which have been
employed in previous blindness prevalence studies [14].
Visual impairment and blindness was defined as per
recently revised WHO guidelines, where visual impair-
ment is defined as presenting visual acuity of less then 6/
18 (0.3 Log MAR), but equal to or better than 3/60 (0.05),
and blindness as presenting visual acuity of 3/60 or worse,
in the better eye [15]. Ophthalmic diagnoses were made
clinically based upon slit lamp biomicroscopic examina-
tion of the anterior segment (eyelids, conjunctiva, cornea,
anterior chamber), and dilated indirect ophthalmoscopy
to provide views of the central and peripheral retina. One
in four examinations were randomly repeated by another
eye care professional; diagnoses were compared after both
examinations were completed and any disagreements
were discussed to arrive at a final diagnosis. In addition
any ophthalmic diagnoses available from the medicalBMC Infectious Diseases 2009, 9:158 http://www.biomedcentral.com/1471-2334/9/158
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cased notes were documented but not revealed to the
examiner(s) prior to examination. The diagnosis of HIV-
related eye conditions such as cytomegalovirus retinitis
(CMVR) was based upon characteristic clinical features
using standardised descriptions [16]. All participants with
active ocular disease (whether or not related to HIV) were
referred to the Ophthalmology Department within Sir JJ
Hospital for further assessment and/or treatment.
Ethics Statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Sir JJ Hos-
pital, and the London School of Hygiene & Tropical Med-
icine Ethics Committee (Ref 5388). Adults who were
about to commence ART were recruited for this study after
obtaining written informed consent.
Data analysis
Information was recorded on a pre-coded data collection
form. All statistical analyses were performed using Stata
10.0IC (Stata Corp. College Station, TX, USA). In analy-
ses, chi-squared tests (and Fisher's exact test where appro-
priate) were used to compare proportions, and the
Wilcoxon rank-sum test to compare medians. Multiple
logistic regression was performed to examine associations
between ocular HIV manifestations and patient demo-
graphic and clinical characteristics. All P-values reported
were two-sided at a 5% significance level.
Results
Study population
One hundred and forty-nine consecutive HIV-infected
participants (298 eyes) were examined (Table 1). All par-
ticipants were of Indian origin, and 93.2% were resident
in Mumbai. The median age of the 149 patients was 36
years (range: 16-65 years), and 104 patients were male
(69.8%). HIV infection was acquired through heterosex-
ual contact, homosexual contact, blood transfusion and
intravenous drug use in 139 (94.6%), 4 (2.7%), 2 (1.3%)
and 2 participants (1.3%), respectively. The main sources
of referral to the ART Centre were private clinics where
patients had undergone HIV testing upon relevant his-
tory/examination findings - patients were thus referred to
the ART Centre to receive free ART and HIV management.
Patients were also referred internally from other specialty
departments within Sir JJ Hospital. The median CD4 cell
count of participants was 180 cells/μL (interquartile range
[IQR], 106-253 cells/μL; range, 18 - 554 cells/μL). 59.7%
(89) participants had symptomatic disease classified as
WHO clinical stages 3 and 4. Over half (53.0%) of the
sample had either current or a previous history of tubercu-
losis (pulmonary and extra-pulmonary).
Ocular manifestations
Overall 7.4% (95% confidence interval [95% CI] 3.8-
12.9%) (n = 11) of the participants complained of any
eye-related symptoms upon direct questioning; this was
mainly related to blurred vision/reduced visual acuity.
Overall, the median presenting visual acuity was 6/9 in
both eyes, ranging from 6/5 to no perception of light
(NPL). The prevalence of any visual impairment (includ-
ing blindness) was 8.5%. (95% CI: 3.8-13.1%) (n = 12).
This included patients with known pre-existing eye dis-
ease - 5 participants had uncorrected refractive error, one
participant had cataracts (age-related), and one had visual
impairment from long-standing ocular trauma.
Ophthalmic manifestations of HIV were detected in 26
patients, giving a prevalence of 17.5% (95% CI: 11.2-
23.6%). Of these only 2 (7.7%) patients had ophthalmic
symptoms (blurred vision, eye pain, floaters). In partici-
pants with no ocular manifestations of HIV, the preva-
lence of any visual impairment was 6.0% compared to
20% in those who did have ocular manifestations (p =
0.02). 4 patients had visual impairment and 1 was blind
in those with HIV-associated ocular disease.
Table 2 shows the overall prevalence of ocular disease and
cause-specific posterior segment (vitreoretinal) disease
within the total study population and within the sub-set
of patients with CD4 counts <200/μL. The most common
ocular manifestation was CMV retinitis (CMVR), which
was present in 13 cases (overall prevalence 8.7%, 95% CI:
4.1-13.3%), Involvement was bilateral in 7/13 cases; there
was one retinal detachment related to CMVR. Four of the
participants with CMVR had visual impairment or blind-
ness but only one patient reported this as a symptom.
HIV retinopathy, as manifested by cotton-wool spots and
retinal haemorrhages, was the second most common oph-
thalmic manifestation, affecting 7 participants, giving a
prevalence of 4.7% (95% CI: 1.3-8.1%) [Table 2]. Disease
was bilateral in all cases and there was impairment of vis-
ual acuity in one case with macular oedema. Choroiditis
was diagnosed in 4 participants; lesions were focal and
spared the macula. Tubercular choroiditis was diagnosed
in 4 cases and all occurred in patients with either a past
history (n = 2) or current history (n = 2) of systemic tuber-
culosis. Neuro-ophthalmic complications included optic
atrophy (1 case, unilateral), and optic disc swelling (1
case, bilateral). Anterior segment complications occurred
in two patients - one had bilateral eyelid molluscum con-
tagiosum, and one had unilateral herpes zoster affecting
the eyelid and forehead (but without corneal involve-
ment). There were no ocular lesions suggestive of Kaposi's
sarcoma.BMC Infectious Diseases 2009, 9:158 http://www.biomedcentral.com/1471-2334/9/158
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Table 1: Characteristics of study participants who did or did not have HIV-related ocular disease (n = 149, unless otherwise specified)
Characteristic Participants with HIV-related ocular 
conditions (%) (n = 26)
Participants without HIV related eye 
conditions (%) (n = 123)
P-value
Median age (n = 148)
Years 38 36 0.95
Gender
Male [n(%)] 18 (69.2) 86 (69.9) 0.94
Marital status
Single 3 (11.5) 13 (10.6) 0.81
Married 20 (76.9) 88 (70.7)
Divorced 0 2 (1.6)
Widowed 3 (11.6) 21 (17.1)
Occupation
None 13 (50.0) 55 (44.7) 0.44
Unskilled 2 (7.7) 22 (17.9)
Skilled 11(42.3) 46 (37.4)
Exposure (n = 147)
Heterosexual 26 (100.0) 113 (93.4) 0.99
Homosexual 0 4 (3.3)
Blood transfusion 0 2 (1.7)
Intravenous drug use 0 2 (1.7)
Median CD4 count
Cells/μL 106 200 0.003
CD4 count (cells/μL)
0-50 7 (26.9) 6 (4.9) 0.003
51-100 6 (23.1) 17 (13.8)
101-150 5 (19.2) 18 (14.6)
151-200 2 (7.7) 23 (18.7)
201-250 2 (7.7) 25 (20.3)
>250 4 (15.4) 34 (27.6)
WHO clinical stage
1/2 2 (7.8) 58(47.2) <0.001
3/4 24 (92.3) 65 (52.8)
Months since HIV diagnosis
≤ 12 11 (42.3) 51 (42.5) 0.94
13-24 6 (23.1) 27 (22.5)
25-60 5 (19.2) 28 (23.3)
>61 4 (15.4) 14 (11.7)
Tuberculosis status
No history 7 (26.9) 63 (51.2) 0.07
Past history 11 (42.3) 31 (25.2)
Current 8 (30.8) 29 (23.6)
History of eye symptoms (n = 148)
None 24 (92.3) 113 (92.6) 0.82
Reduced vision 2 (7.7) 6 (4.9)
Pain 0 2 (1.6)
Floaters 0 1 (0.8)
Visual acuity (n = 142)
None 20 (80.0) 110 (94.0) 0.02
Visual impairment 4 (16.0) 7 (5.6)
Blind 1 (4.0) 0BMC Infectious Diseases 2009, 9:158 http://www.biomedcentral.com/1471-2334/9/158
Page 5 of 9
(page number not for citation purposes)
Risk Factors for HIV-Associated Eye Disease
Table 1 shows the characteristics of groups of patients
with and without HIV-associated eye disease. There were
no significant differences between the two groups in gen-
der, age, marital status, occupation and duration since
HIV diagnosis. However, patients with eye disease had
more advanced immunodeficiency as reflected by signifi-
cantly lower CD4 cell counts and more advanced WHO
stage of disease. Overall the prevalence of eye disease
among patients with CD4 cell counts ≤ 200 cells/μL was
23.8% (95% CI: 14.5-33.1%), compared to 9.2% (95%
CI: 2.0-16.4%), among those with CD4 cell counts ≤ 200
cells/μL (p = 0.02). There was also a strong trend for a cur-
rent or previous history of TB to be associated with eye dis-
ease (Table 1). Although patients with eye disease were
significantly more likely to have impaired visual acuity,
Table 2: Prevalence of ocular disease and posterior segment infections, by CD4 counts.
Condition No of cases:
CD4 count <200 cells/μL
(n = 84)
Prevalence
(95% CI)
No of cases:
All CD4 counts
(n = 149)
Prevalence
(95% CI)
Any ocular condition 18 23.8% (14.5-33.1) 26 17.5% (11.2-23.6)
Vitreoretinal infection (CMVR & TB) 13 15.5% (7.6-23.3) 17 11.4% (6.2-16.6)
CMVR 10 11.9% (4.8-19.0) 13 8.7% (4.1-13.3)
TB choroiditis 3 3.7% (0.04-7.6) 4 2.7% (0.05-5.3)
HIV retinopathy 7 8.7% (2.2-14.3) 7 4.7% (1.3-8.1)
Table 3: Multivariable analysis for risk factors for ocular manifestations of HIV, among patients prior to commencing ART (n = 135).
Variable Odds ratio (OR) for ocular manifestation of HIV 95% CI P-value
Age group (years)
16-30 1 - 0.2
31-35 0.1 0.02-0.7
36-40 0.6 0.1-2.5
41-45 0.7 0.1-3.3
>46 0.6 0.1-3.2
Sex
Male 1 - 0.67
Female 1.3 0.4-5.0
CD4 count (cells/μL)
>201 1 - 0.02
101-200 1.3 0.3-5.4
0-100 6.3 1.5-26.3
WHO clinical stage
1 or 2 1 - 0.001
3 or 4 9.4 2.4-37.2
Visual acuity
Normal 1 - 0.14
Visual impairment/blind 3.1 0.7-14.0
Ocular symptoms
No 1 - 0.95
Yes 1.1 0.1-7.8
Duration of disease (months)
≤ 12
13-24 1 - 0.8
25-60 0.9 0.2-3.4
>60 0.5 0.1-2.2
0.5 0.1-3.0BMC Infectious Diseases 2009, 9:158 http://www.biomedcentral.com/1471-2334/9/158
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there was no difference in the frequency of reported symp-
toms between the two groups (Table 1).
Analysis of the distribution of the various ocular manifes-
tations of HIV by CD4 count revealed that all participants
who were diagnosed with CMVR, and who were ART-
naïve at the time of the study had CD4 counts ≤ 200 cells/
μL. (3/13 CMVR cases were previously treated with ART by
private physicians, and had CD4 counts >200 cells/μL at
their time of entry to our study). The median CD4 count
was 138 cells/μL, (IQR = 67.5-188.5 cells/μL; range = 30-
554 cells/μL) and all patients with active CMVR had CD4
counts <200/μL. The majority (71.4%) of participants
with HIV retinopathy were categorised at WHO clinical
stage 3 or 4, and all had CD4 counts ≤ 150 cells/μL. The
median CD4 count in cases of tubercular choroiditis was
29 cells/μL. Overall, 76.9% of the study population with
HIV-associated ocular conditions had CD4 counts ≤ 200
cells/μL.
Multivariable analysis, adjusting for baseline characteris-
tics significant at a 5% significance level and a priori con-
founders, showed that a low CD4 count (≤ 100 cells/μL),
and WHO clinical stages 3 and 4 were independently
associated with increased odds of having an ocular mani-
festation of HIV (Table 3). (The presence of systemic TB
was initially included as a co-variate in the regression
model, but due to its high correlation with WHO clinical
stage, both parameters could not be fitted and thus only
WHO clinical stage was retained due to its strong clinical
and statistical association with ocular disease).
Sensitivity and specificity analyses
Ocular symptoms (ascertained using the standardised
symptom screening questionnaire) were not independ-
ently predictive of ocular disease and although the specif-
icity for HIV-related eye disease was high (92%; 95%CI:
86.1-96.3%), the sensitivity and positive predictive value
were very low (7.7%, 95% CI: 1.3-26.6% and 18%,
95%CI: 3.2-52.2%, respectively) (Table 4). Analyses were
conducted to ascertain the proportion of participants with
HIV ocular complications that would be detected if only
subsets of higher risk (e.g. low C4 count, history of TB)
were screened. Using WHO clinical stage 3/4 as a screen-
ing subset for HIV eye disease led to a sensitivity of 92.3%
(95% CI: 73.4-98.6%), and specificity of 52.8% (95% CI:
43.7-61.8%). There was no clear CD4 count threshold
above which led to a marked increment in sensitivity.
With decreasing CD4 counts, specificity and PPV
increased (Table 4). The number needed to screen (NNS)
is the number of people that need to be screened to detect
one new case of eye disease. The lowest NNS was found
using vision status, screening those with visual impair-
ment in one eye gave a NNS of 2.4 (95%CI: 1.4-6.0).
Overall, the NNS was lower the more advanced the degree
of immunodeficiency as manifested by CD4 count and
WHO clinical status.
Table 4: Sensitivity/specificity analysis using CD4 count thresholds, WHO clinical status, TB status, presence of ocular symptoms, 
presence of visual impairment
Factor Number with HIV 
eye disease 
(n = 26)
Number without 
HIV eye disease
Sensitivity Specificity Positive 
predictive value
Number needed 
to screen* 
(95%CI)
(n = 123) (95% CI) (95% CI) (95% CI)
WHO Clinical 
status
Stage 1/2 2 58 7.7 (1.3-26.6) 52.8 (43.7-61.8) 3.3 (0.6-12.5) 30.3 (8-166.7)
Stage 3/4 24 65 92.3 (73.4-98.6) 47.2 (38.2-56.3) 27.0 (18.3-37.6) 3.7 (2.9-5.5)
TB status
Past/current TB 19 60 73.1 (52.0-87.6) 51.2 (42.0-60.2) 24.1 (15.4-35.2) 4.1 (2.9-6.5)
CD4 count (cells/
μL)
≤ 50 7 6 27.0 (12.4-48.0) 95.1 (89.2-98.0) 53.8 (26.1-78.0) 1.9 (1.3-3.8)
≤ 100 13 23 50.0 (30.4-69.6) 81.3 (73.1-87.5) 36.1 (21.3-53.8) 2.8 (1.9-4.7)
≤ 150 18 41 69.2 (48.1-84.9) 66.7 (57.5-74.8) 30.5 (19.5-44.0) 3.3 (2.3-5.1)
≤ 200 20 64 76.9 (55.9-90.2) 48.0 (38.9-57.1) 23.9 (15.5-34.6) 4.2 (2.9-6.5)
≤ 250 22 89 84.6 (64.3-95.0) 27.6 (20.1-36.6) 19.8 (13.1-28.7) 5.1 (3.5-7.6)
Ocular symptoms
Present 2 9 7.7 (4.0-13.2) 92.6 (86.1-96.3) 18.1 (3.2-52.2) 5.5 (1.9-31.2)
Vision status
Visual impairment 5 7 20.0 (7.6-41.3) 94.0 (87.6-97.3) 41.7 (16.5-71.4) 2.4 (1.4-6.0)
*The number needed to screen (NNS) is the number of people that need to be screened to detect one new case of eye diseaseBMC Infectious Diseases 2009, 9:158 http://www.biomedcentral.com/1471-2334/9/158
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Discussion
This study evaluated the prevalence of ocular disease in
HIV-infected patients referred to an ART service in India,
regardless of whether patients reported ocular or visual
symptoms. Ophthalmic manifestations of HIV were
found in over a fifth of patients and the most common
manifestations were due to opportunistic vitreoretinal
infections, particularly CMVR. These findings are impor-
tant with regard to policies for screening for ocular disease
prior to ART. Screening in this patient population is par-
ticularly important not only because of the high preva-
lence of disease in this highly immunocompromised
patient group but also in view of the potential for worsen-
ing of ocular disease due to ART-induced IRIS.
The overall prevalence of HIV-associated ocular disease in
this population was 17.5%, and 23.4% in those with CD4
counts <200 cells/μL. Other studies in India have reported
prevalence estimates ranging between 8 and 45%, with
study numbers ranging from 100-112 participants. Higher
prevalence estimates in other studies may result from the
study of patients referred to a tertiary ophthalmic centre,
evaluation of patients based upon symptoms or inclusion
of patients after initiation of ART in whom complications
of IRIS have been present [4,11,12]. Our study is the larg-
est prevalence study of HIV ocular manifestations in India
to date, and the participants in our study are likely to be a
representative sample of ART-naïve HIV-infected persons
presenting for ART treatment and care within a large
Indian metropolis. A key strength of this study is that all
patients were examined regardless of the presence or
absence of ocular symptoms.
Our findings are consistent with other prevalence studies
in Indian populations of HIV-infected patients in whom
retinal/posterior segment disease is the most common
finding [4,11,12]. CMVR continues to be the most com-
mon ocular finding in India, and may affect up to 11.9%
of patients with CD4 counts <200 cells/μL. With the high
prevalence (73.1%) of systemic TB (either past or current)
in the study population, it is not surprising that cases of
tubercular choroiditis were also seen. All patients with
ocular (choroidal) TB had a co-existent history of systemic
TB. This may have implications in terms of any subse-
quent immune reconstitution-mediated phenomena that
are strongly associated with disseminated forms of TB
[17]. We found that 15.5% of patients with CD4 counts
<200 cells/μL had retinal infections which are known to
predispose to immune recovery uveitis (IRU). Thus, as
access to ART expands nationwide, Indian patients may be
at high risk of visual loss upon commencement of ART,
whether due to the direct adverse effects of opportunistic
disease, or immune-reconstitution mediated-phenom-
ena. Future prospective studies are needed to examine
this.
There were very few cases of anterior segment disease (eye-
lids, conjunctiva, cornea), which is in keeping with find-
ings from other Indian studies [4,11]. There were no
ocular lesions of Kaposi's sarcoma in this sample which is
in agreement with the very low prevalence of AIDS-related
malignancies in South Asia [18], and is thought to be due
to low seroprevalence of human herpes virus-8 (HHV-8)
in these populations [19].
The prevalence of ophthalmic lesions associated with HIV
was significantly higher in patients with CD4 counts
between 0-100 cells/μL, and in those with WHO clinical
stages 3 or 4 (Table 1). We found that those with CD4
counts <100 cells/μL were six times more likely to have an
ocular HIV-related lesion, and those with advanced HIV as
defined by WHO clinical stage were nine times more
likely to be at risk, after adjustment for potential con-
founders (Table 3). Thus CD4 count and WHO clinical
stage may be important predictors of the presence of HIV-
related eye disease in an ART-naïve population. Our find-
ing that 76.9% of patients with ocular manifestations of
HIV had CD4 counts <200 cells/μL is comparable with the
results of the one other study in which CD4 cell count
measurements were available [11].
It is interesting to note that out of 12 patients with visual
impairment in the overall study sample, only one com-
plained of reduced visual acuity. In addition, of these 12
patients, 5 had non HIV-related treatable/correctable con-
ditions. The reporting of ocular symptoms was low
(<10%) in groups of patients with and without ocular dis-
ease. This may reflect genuine non-report due to symp-
toms not being perceived by patients as important.
Alternatively, it has been suggested that patients with HIV
may not seek treatment for ocular conditions due a per-
ceived stigma related to HIV [12,20]. Despite similar
reporting of ophthalmic symptoms between the two
groups, patients with HIV-associated eye disease were sig-
nificantly more likely to have visual acuities consistent
with blindness or visual impairment than the group with-
out ocular conditions. The poor association between ocu-
lar disease and ocular symptoms is important to note as
often patients will seek ophthalmic examination only if
they have visual complaints or symptoms. The combina-
tion of visual impairment and HIV infection may lead to
increased economic dependency for the individual and
their family, as well as a psychosocial impact with loss of
self-esteem and possible family neglect [20].
Conclusion
Current practice at several ART centres in India is to refer
patients for an ophthalmic examination only upon com-
plaint of ocular symptoms or after a physician has noted
abnormal ocular signs on medical examination. Our find-
ings highlight the need for routine baseline ophthalmicBMC Infectious Diseases 2009, 9:158 http://www.biomedcentral.com/1471-2334/9/158
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screening at the pre-ART stage. The findings of this study,
particularly the low sensitivity and PPV of ocular symp-
tom screening in this population suggest that utilising
patients' subjective description of ocular complaints is not
a reliable method for detecting HIV-associated ocular dis-
ease. However, detection of CMVR using a symptom-ori-
ented approach has produced diverse findings. In the
USA, studies suggest the percentage of individuals with
CMVR reporting ocular symptoms lies anywhere between
23-88% [21-23], and in South East Asia, the estimate is
between 31-44% [24].
Routine baseline ophthalmic screening of all patients may
be particularly important for conditions such as CMVR or
TB choroiditis, where if a lesion is peripherally located
within the retina the patient may not experience reduction
in visual acuity, or may not place significance upon the
presence of floaters or other ocular symptoms. If such a
lesion is not detected and treated at an early stage it may
extend to the posterior pole (optic disc and macula), lead-
ing to potentially blinding complications either due to the
direct pathological effects of opportunistic disease, or due
immune-reconstitution mediated-phenomena once ART
is commenced.
Further work is indicated to formally evaluate the validity
of patients' symptoms in detecting different types of HIV-
associated ocular disease. It is possible that specificity and
sensitivity using symptoms as a screen for detecting ocular
diseases varies by anatomical location (i.e. anterior seg-
ment vs. posterior segment), and this information may be
of value in resource-limited settings where a full ophthal-
mic evaluation in every patient is not possible. Conduct-
ing a full ophthalmic examination requires trained
personnel and adequate resources that may be difficult or
impossible to provide for all patients in resource-limited
countries. However, where possible, we suggest that an
ophthalmic examination prior to commencing ART is of
value in order to reduce HIV-related ocular morbidity in
the era of increased ART availability in India. HIV treat-
ment programs in resource-poor settings are unlikely to
provide ophthalmic screening for all patients. The results
of our sensitivity and specificity analyses suggest that oph-
thalmic screening examinations might be prioritised for
subsets of patients with advanced immunodeficiency as
manifested by WHO clinical status 3 or 4, and the pres-
ence of systemic TB.
With the advent of increased ART availability, life expect-
ancy for HIV-infected persons is likely to improve. How-
ever, the burden of HIV-related ocular disease is likely to
remain stable or even increase with possible immune
reconstitution ocular complications. Strategies for screen-
ing high-risk populations for HIV-related ocular disease
are needed as well as provision for the management and
treatment of these conditions once detected.
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